NASDAQ:SLGL Sol-Gel Technologies (SLGL) Stock Forecast, Price & News $3.60 +0.26 (+7.78%) (As of 05/26/2023 08:47 PM ET) Add Compare Share Share Today's Range$3.32▼$3.6050-Day Range$3.26▼$4.2752-Week Range$3.10▼$6.89Volume14,200 shsAverage Volume18,046 shsMarket Capitalization$83.27 millionP/E RatioN/ADividend YieldN/APrice Target$11.50 ProfileProfileAnalyst RatingsChartCompetitorsEarningsFinancialsInstitutional OwnershipHeadlinesSEC FilingsShort InterestSocial MediaProfileAnalyst RatingsChartCompetitorsEarningsFinancialsInstitutional OwnershipHeadlinesSEC FilingsShort InterestSocial Media Sol-Gel Technologies MarketRank™ ForecastAnalyst RatingBuy3.00 Rating ScoreUpside/Downside219.4% Upside$11.50 Price TargetShort InterestHealthy0.42% of Float Sold ShortDividend StrengthN/ASustainabilityN/ANews Sentiment1.28Based on 3 Articles This WeekInsider TradingN/AProj. Earnings GrowthGrowingFrom ($0.63) to ($0.39) Per ShareSee Full Details Hide Full Details Overall MarketRank™MarketRank is calculated as an average of available category scores, with extra weight given to analysis and valuation.2.37 out of 5 starsMedical Sector249th out of 1,010 stocksPharmaceutical Preparations Industry104th out of 494 stocks 3.5 Analyst's Opinion Consensus RatingSol-Gel Technologies has received a consensus rating of Buy. The company's average rating score is 3.00, and is based on 1 buy rating, 1 hold rating, and no sell ratings.Price Target Upside/DownsideAccording to analysts' consensus price target of $11.50, Sol-Gel Technologies has a forecasted upside of 219.4% from its current price of $3.60.Amount of Analyst CoverageSol-Gel Technologies has only been the subject of 2 research reports in the past 90 days. Previous Next 5.0 Short Interest Percentage of Shares Shorted0.42% of the float of Sol-Gel Technologies has been sold short.Short Interest Ratio / Days to CoverSol-Gel Technologies has a short interest ratio ("days to cover") of 2.9, which is generally considered an acceptable ratio of short interest to trading volume.Change versus previous monthShort interest in Sol-Gel Technologies has recently decreased by 24.45%, indicating that investor sentiment is improving significantly. Previous Next 0.0 Dividend Strength Dividend YieldSol-Gel Technologies does not currently pay a dividend.Dividend GrowthSol-Gel Technologies does not have a long track record of dividend growth. Previous Next N/A Sustainability and ESG Overall ESG (Environmental, Social, and Governance) ScoreThere is no current Upright™ data available for SLGL. Previous Next 2.9 News and Social Media Coverage News SentimentSol-Gel Technologies has a news sentiment score of 1.28. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a higher news sentiment than the 0.75 average news sentiment score of Medical companies.News Coverage This WeekMarketBeat has tracked 3 news articles for Sol-Gel Technologies this week, compared to 1 article on an average week. Previous Next 1.7 Company Ownership Insider Buying vs. Insider SellingIn the past three months, Sol-Gel Technologies insiders have not sold or bought any company stock.Percentage Held by Insiders66.51% of the stock of Sol-Gel Technologies is held by insiders. A high percentage of insider ownership can be a sign of company health.Percentage Held by InstitutionsOnly 25.09% of the stock of Sol-Gel Technologies is held by institutions. Previous Next 0.6 Earnings and Valuation Earnings GrowthEarnings for Sol-Gel Technologies are expected to grow in the coming year, from ($0.63) to ($0.39) per share.Price to Earnings Ratio vs. the MarketThe P/E ratio of Sol-Gel Technologies is -4.39, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Earnings Ratio vs. SectorThe P/E ratio of Sol-Gel Technologies is -4.39, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Book Value per Share RatioSol-Gel Technologies has a P/B Ratio of 1.97. P/B Ratios below 3 indicates that a company is reasonably valued with respect to its assets and liabilities. Previous Next See Top Rated MarketRank™ Stocks Here About Sol-Gel Technologies (NASDAQ:SLGL) StockSol-Gel Technologies Ltd. is a clinical-stage dermatology company, which engages in the identification, development, and commercialization of topical dermatological drug products for the treatment of skin diseases. Its products include VERED, TWIN, and SIRS-T. The company was founded by David Avnir and Alon Seri-Levy on October 28, 1997 and is headquartered in Ness Ziona, Israel.Read More Receive SLGL Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Sol-Gel Technologies and its competitors with MarketBeat's FREE daily newsletter. Email Address SLGL Stock News HeadlinesMay 27, 2023 | americanbankingnews.comSol-Gel Technologies Ltd. (NASDAQ:SLGL) Short Interest UpdateMay 12, 2023 | finanznachrichten.deSol-Gel Technologies Ltd.: Sol-Gel Technologies Reports First Quarter 2023 Financial Results and Provides Corporate UpdateMay 29, 2023 | Behind the Markets (Ad)[BREAKING] New "Living Missile" to Replace Nuclear MissilesCBS News Reports: "It's an entirely new type of weapon." The New York Times Reports: "No existing defense can stop it." And one small company is building them for the Pentagon!May 12, 2023 | finance.yahoo.comSol-Gel Technologies Ltd. (SLGL) Reports Q1 Loss, Tops Revenue EstimatesMay 12, 2023 | finance.yahoo.comSol-Gel Technologies Reports First Quarter 2023 Financial Results and Provides Corporate UpdateApril 22, 2023 | finance.yahoo.comCompanies Like Sol-Gel Technologies (NASDAQ:SLGL) Can Afford To Invest In GrowthApril 16, 2023 | americanbankingnews.comQ1 2023 EPS Estimates for Sol-Gel Technologies Ltd. (NASDAQ:SLGL) Decreased by AnalystApril 15, 2023 | americanbankingnews.comHC Wainwright Reaffirms Buy Rating for Sol-Gel Technologies (NASDAQ:SLGL)May 29, 2023 | Behind the Markets (Ad)[BREAKING] New "Living Missile" to Replace Nuclear MissilesCBS News Reports: "It's an entirely new type of weapon." The New York Times Reports: "No existing defense can stop it." And one small company is building them for the Pentagon!April 13, 2023 | msn.comHC Wainwright & Co. Reiterates Sol-Gel Technologies (SLGL) Buy RecommendationApril 12, 2023 | markets.businessinsider.comH.C. Wainwright Keeps Their Buy Rating on Sol-Gel Technologies (SLGL)March 20, 2023 | finance.yahoo.comSol-Gel Technologies to Present at the H.C. Wainwright Autoimmune & Inflammatory Disease Virtual ConferenceMarch 20, 2023 | finance.yahoo.comSol-Gel Technologies to Present at the H.C. Wainwright Autoimmune & Inflammatory Disease Virtual ConferenceMarch 10, 2023 | finanznachrichten.deSol-Gel Technologies Ltd.: Sol-Gel Reports Full-Year 2022 Financial Results and Corporate DevelopmentsMarch 10, 2023 | finance.yahoo.comSol-Gel Technologies Ltd. (SLGL) Reports Q4 Loss, Lags Revenue EstimatesMarch 10, 2023 | finance.yahoo.comSol-Gel Reports Full-Year 2022 Financial Results and Corporate DevelopmentsFebruary 28, 2023 | seekingalpha.comSLGL Sol-Gel Technologies Ltd.February 27, 2023 | finance.yahoo.comCould The Market Be Wrong About Sol-Gel Technologies Ltd. (NASDAQ:SLGL) Given Its Attractive Financial Prospects?January 27, 2023 | msn.comSol-Gel to acquire rare disorder drug patidegib for $4.7M upfront; plans $22.8M offeringsJanuary 27, 2023 | finance.yahoo.comSol-Gel Acquires Patidegib, a Phase 3, FDA-Breakthrough-Designated Orphan Product Candidate to Pursue Potential Market of Over $300 MillionJanuary 27, 2023 | finance.yahoo.comSol-Gel Announces Aggregate $22.8 Million Concurrent Registered Direct and Private Placement OfferingsDecember 8, 2022 | finance.yahoo.comZacks Industry Outlook Highlights Dr. Reddy's, Amphastar Pharmaceuticals and Sol-Gel TechnologiesDecember 7, 2022 | finance.yahoo.com3 Generic Drug Stocks to Watch Amid Inflation PressuresNovember 10, 2022 | finance.yahoo.comSol-Gel Technologies Reports Third Quarter 2022 Financial Results and Provides Corporate UpdateNovember 4, 2022 | finance.yahoo.comSol-Gel Technologies (NASDAQ:SLGL) investors are sitting on a loss of 45% if they invested a year agoOctober 24, 2022 | msn.comNasdaq Turns Higher; Applied Genetic Technologies Shares SurgeOctober 3, 2022 | finance.yahoo.comSol-Gel Technologies Appoints Michael Glezin Vice President, Business DevelopmentSee More Headlines View Price History Chart DataSkip Price History Chart 30 days | 90 days | 365 days | Advanced Chart Receive SLGL Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Sol-Gel Technologies and its competitors with MarketBeat's FREE daily newsletter. Email Address SLGL Company Calendar Last Earnings3/10/2023Today5/29/2023Next Earnings (Estimated)8/03/2023Fiscal Year End12/31/2023Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeNASDAQ Industry Pharmaceutical preparations Sub-IndustryN/A SectorMedical Current SymbolNASDAQ:SLGL CUSIPN/A CIK1684693 Webwww.sol-gel.com Phone(728) 931-3433Fax972-153-523044444Employees65Year Founded1997Price Target and Rating Average Stock Price Forecast$11.50 High Stock Price Forecast$19.00 Low Stock Price Forecast$5.50 Forecasted Upside/Downside+219.4%Consensus RatingBuy Rating Score (0-4)3.00 Research Coverage3 Analysts Profitability EPS (Most Recent Fiscal Year)($0.82) Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet Income$-14,920,000.00 Net Margins-422.45% Pretax Margin-422.45% Return on Equity-42.56% Return on Assets-38.80% Debt Debt-to-Equity RatioN/A Current Ratio10.37 Quick Ratio10.37 Sales & Book Value Annual Sales$3.88 million Price / Sales21.46 Cash FlowN/A Price / Cash FlowN/A Book Value$1.90 per share Price / Book1.89Miscellaneous Outstanding Shares23,130,000Free Float7,746,000Market Cap$83.27 million OptionableNot Optionable Beta1.29 Social Links Key ExecutivesAlon Seri-LevyChief Executive Officer & DirectorItzik YosefChief Operating OfficerGilad MamlokChief Financial OfficerOfer ToledanoVice President-Research & DevelopmentOfra Levy-HachamVP-Clinical & Regulatory AffairsKey CompetitorsSyros PharmaceuticalsNASDAQ:SYRSEliem TherapeuticsNASDAQ:ELYMHookipa PharmaNASDAQ:HOOKXilio TherapeuticsNASDAQ:XLOBellerophon TherapeuticsNASDAQ:BLPHView All CompetitorsInstitutional OwnershipArmistice Capital LLCBought 2,408,000 shares on 5/16/2023Ownership: 10.411%Kingdon Capital Management L.L.C.Sold 61,835 shares on 5/15/2023Ownership: 3.333%Simplex Trading LLCBought 500 shares on 4/27/2023Ownership: 0.000%Raymond James Financial Services Advisors Inc.Bought 9,656 shares on 4/14/2023Ownership: 0.255%Raymond James & AssociatesBought 4,432 shares on 4/14/2023Ownership: 0.158%View All Institutional Transactions SLGL Stock - Frequently Asked Questions Should I buy or sell Sol-Gel Technologies stock right now? 3 Wall Street research analysts have issued "buy," "hold," and "sell" ratings for Sol-Gel Technologies in the last twelve months. There are currently 1 hold rating, 1 buy rating and 1 strong buy rating for the stock. The consensus among Wall Street research analysts is that investors should "buy" SLGL shares. View SLGL analyst ratings or view top-rated stocks. What is Sol-Gel Technologies' stock price forecast for 2023? 3 Wall Street research analysts have issued 12 month price targets for Sol-Gel Technologies' shares. Their SLGL share price forecasts range from $5.50 to $19.00. On average, they expect the company's stock price to reach $11.50 in the next twelve months. This suggests a possible upside of 219.4% from the stock's current price. View analysts price targets for SLGL or view top-rated stocks among Wall Street analysts. How have SLGL shares performed in 2023? Sol-Gel Technologies' stock was trading at $4.5599 at the start of the year. Since then, SLGL stock has decreased by 21.1% and is now trading at $3.60. View the best growth stocks for 2023 here. Are investors shorting Sol-Gel Technologies? Sol-Gel Technologies saw a decrease in short interest in May. As of May 15th, there was short interest totaling 48,200 shares, a decrease of 24.5% from the April 30th total of 63,800 shares. Based on an average daily volume of 16,600 shares, the short-interest ratio is presently 2.9 days. Currently, 0.4% of the company's stock are short sold. View Sol-Gel Technologies' Short Interest. When is Sol-Gel Technologies' next earnings date? The company is scheduled to release its next quarterly earnings announcement on Thursday, August 3rd 2023. View our SLGL earnings forecast. How were Sol-Gel Technologies' earnings last quarter? Sol-Gel Technologies Ltd. (NASDAQ:SLGL) posted its quarterly earnings results on Friday, March, 10th. The company reported ($0.25) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.13) by $0.12. The business had revenue of $0.10 million for the quarter, compared to analyst estimates of $1.85 million. Sol-Gel Technologies had a negative trailing twelve-month return on equity of 42.56% and a negative net margin of 422.45%. What ETF holds Sol-Gel Technologies' stock ? Invesco Raymond James SB-1 Equity ETF holds 9,374 shares of SLGL stock, representing 0.03% of its portfolio. What other stocks do shareholders of Sol-Gel Technologies own? Based on aggregate information from My MarketBeat watchlists, some companies that other Sol-Gel Technologies investors own include NVIDIA (NVDA), Advanced Micro Devices (AMD), Flexion Therapeutics (FLXN), Iovance Biotherapeutics (IOVA), Marker Therapeutics (MRKR), Teva Pharmaceutical Industries (TEVA), Viking Therapeutics (VKTX), Verona Pharma (VRNA) and Adaptimmune Therapeutics (ADAP). When did Sol-Gel Technologies IPO? (SLGL) raised $60 million in an IPO on Thursday, February 1st 2018. The company issued 5,000,000 shares at a price of $11.00-$13.00 per share. Jefferies and BMO Capital Markets acted as the underwriters for the IPO and JMP Securities and Raymond James were co-managers. What is Sol-Gel Technologies' stock symbol? Sol-Gel Technologies trades on the NASDAQ under the ticker symbol "SLGL." Who are Sol-Gel Technologies' major shareholders? Sol-Gel Technologies' stock is owned by many different retail and institutional investors. Top institutional investors include Armistice Capital LLC (10.41%), Kingdon Capital Management L.L.C. (3.33%), Raymond James Financial Services Advisors Inc. (0.26%), Raymond James & Associates (0.16%) and Simplex Trading LLC (0.00%). How do I buy shares of Sol-Gel Technologies? Shares of SLGL stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab. Compare Top Brokerages Here. What is Sol-Gel Technologies' stock price today? One share of SLGL stock can currently be purchased for approximately $3.60. How much money does Sol-Gel Technologies make? Sol-Gel Technologies (NASDAQ:SLGL) has a market capitalization of $83.27 million and generates $3.88 million in revenue each year. The company earns $-14,920,000.00 in net income (profit) each year or ($0.82) on an earnings per share basis. How can I contact Sol-Gel Technologies? Sol-Gel Technologies' mailing address is 7 GOLDA MEIR ST. WEIZMANN SCIENCE PARK, NESS ZIONA L3, 7403648. The official website for the company is www.sol-gel.com. The company can be reached via phone at (728) 931-3433, via email at crusso@soleburytrout.com, or via fax at 972-153-523044444. This page (NASDAQ:SLGL) was last updated on 5/29/2023 by MarketBeat.com Staff Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Sol-Gel Technologies Ltd. Please log in to your account or sign up in order to add this asset to your watchlist. Get 30 Days of MarketBeat All Access Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools: Best-in-Class Portfolio Monitoring View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio. Stock Ideas and Recommendations Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report. Advanced Stock Screeners and Research Tools Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis. Start Your 30-Day Free Trial Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Your Password: or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Choose a Password: Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.